North America Biomarkers Market

The North America biomarkers market is expected to reach USD 42.25 billion by 2030, from USD 25.13 billion in 2025, reporting a CAGR of 11.0% between 2025 and 2030. The growth of the North America biomarkers market is driven by several key factors, including the adoption of precision medicine and companion diagnostics, as well as advancing healthcare infrastructure and R&D investment.

To know about the assumptions considered for the study download the pdf brochure

Several key players in the North America biomarkers industry include Abbott (US), Thermo Fisher Scientific Inc (US), Revvity (US), Laboratory Corporation Of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc (US), Agilent Technologies, Inc (US), Quanterix (US), among others. Companies in this market are pursuing expansion strategies to strengthen their global footprint and advance their technology portfolios. In November 2025, Abbott announced plans to acquire Exact Sciences to bolster its position in the biomarker and cancer diagnostics market, expand its portfolio of screening and precision oncology assays, and strengthen its presence in biomarker-based testing.

Abbott (US)

Abbott is a leading player in the North American biomarker market. The company has strong immunoassay and molecular diagnostics portfolios that enable earlier, more precise disease detection. The company acquired Exact Sciences, adding high-growth cancer screening and precision oncology tests that broaden its biomarker offerings in colorectal and multi-cancer early detection. The deal is expected to strengthen Abbott's technology portfolio, expand its installed base among health systems, and make advanced biomarker-driven diagnostics more accessible across the region.

Thermo Fisher Scientific (US)

Thermo Fisher Scientific (US) is a key player in the North American biomarker market. Its offerings include immunoassay, next-generation sequencing, and mass spectrometry platforms to help researchers and clinicians detect disease earlier and tailor treatment more precisely. The company continues to invest in precision oncology and companion diagnostics, bringing together instruments, assays, and software to enable hospitals and labs to translate complex biomarker signals into clear, actionable answers for patients across the region.

Revvity (US)

Revvity is also a leader in the North American biomarker market, providing labs with end-to-end tools for discovering and measuring DNA, RNA, protein, and imaging biomarkers across cancer and other diseases. Through multi-omic platforms, NGS workflows, immunoassays, and reference standards, the company enables researchers to transform complex biological signals into clear insights, supporting earlier diagnosis, informed therapy selection, and enhanced monitoring of treatment response.

Market Ranking

The North America biomarkers market is marked by strong consolidation, with a few major diagnostics players shaping how biomarkers move from research into everyday care. Abbott (US) leverages its broad immunoassay and molecular portfolios, along with its planned acquisition of Exact Sciences, to expand cancer screening and precision oncology testing across hospital and reference laboratory networks. Thermo Fisher Scientific (US) reinforces its position with powerful NGS, mass spectrometry, and companion diagnostic solutions that support end-to-end biomarker discovery and clinical deployment. Revvity (US) enhances depth with multi-omic platforms, biomarker discovery tools, and IVD reference standards, enabling labs to translate complex signals into actionable insights for earlier diagnosis and more informed therapy selection. Laboratory Corporation of America Holdings (US) and Charles River Laboratories (US) complement these technology providers with extensive central laboratory testing, preclinical biomarker services, and specialty assay development, providing biopharma and clinicians with integrated support from discovery through clinical trials and routine patient testing.

Related Reports:

North America Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)-Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com